Q3: 2025-11-06 Earnings Summary
EPS of $0.05 misses by $0.05
| Revenue of $479.53M (-22.83% Y/Y) beats by $10.94M
Evolent Health, Inc. (EVH) Q3 2025 Earnings Call November 6, 2025 5:00 PM EST
Company Participants
Seth Blackley – Co-Founder, CEO & Director
John Johnson – Chief Financial Officer
Conference Call Participants
Kevin Caliendo – UBS Investment Bank, Research Division
Daniel Grosslight – Citigroup Inc., Research Division
John Stansel – JPMorgan Chase & Co, Research Division
Lucas Romanski – TD Cowen, Research Division
Eduardo Ron – Truist Securities, Inc., Research Division
Jeffrey Garro – Stephens Inc., Research Division
Jessica Tassan – Piper Sandler & Co., Research Division
David Larsen – BTIG, LLC, Research Division
Matthew Shea – Needham & Company, LLC, Research Division
Matthew Gillmor – KeyBanc Capital Markets Inc., Research Division
Presentation
Operator
Welcome to the Evolent Earnings Conference Call for the Third Quarter ended September 30, 2025. As a reminder, this conference call is being recorded. Your host for the call today from Evolent are Seth Blackley, Chief Executive Officer; and John Johnson, Chief Financial Officer. This call will be archived and available later this evening and for the next week via the webcast on the company’s website in the section titled Investor Relations.
This conference call will contain forward-looking statements under the U.S. federal laws. These statements are subject to risks and uncertainties that could cause actual results to differ materially from historical experience or present expectations. A description of some of the risks and uncertainties can be found in the company’s reports that are filed with the Securities and Exchange Commission, including cautionary statements included in our current and periodic filings. For additional information on the company’s results and outlook, please refer to our third quarter press release issued earlier today.
Finally, as a reminder, reconciliations of non-GAAP measures discussed during today’s call to the most direct comparable GAAP measures are available in the summary presentation available in the Investor Relations section of our website or
